Latest research on the coronavirus, variants, vaccine efficacy, treatment protocols, and guidelines

Introduction

JN.1 and HV.1 are the latest variants, affecting 44 percent and 22 percent of the United States population as per Center for Disease Prevention and Control. Both the strains are related to the omicron variant.

The EG.5 variant, also called Eris peaked in the fall and eventually declined in September in the United States. EG.5 is an omicron descendant, and the mutation helped it surpass antibodies developed by the immune system.

HV.1 is a descendant of EG.5 and it took over EG.5 in October. Neither of them is more contagious, and the prevailing diagnostic tests and treatments continue to be effective against them.

Recent research published in December showed that antibodies produced in response to the new vaccine targeting a related XBB variant are protective against both EG.5 and HV.1

BA.2.86 (Pirola) is another variant of concern. It had multiple mutations in the spike protein that increased its pathogenicity. As per earlier data, the vaccines might not be effective against this strain; however, evidence suggests that boosters stimulate sufficient antibodies for immunity.

Another study found that BA.2.86 may not be as transmissible as other variants. It is still unclear if JN.1 affects the ability to infect people or cause more severe illness.

The Vaccine Efficacy

Published randomized controlled trials, cohort studies, and case-control studies are used to evaluate vaccine effectiveness against variants of concern (Alpha, Beta, Gamma, Delta, and Omicron).

Full vaccination was effective against the variants with an efficacy of 88% (Alpha), 73% (Beta), 63% (Gamma), Delta (77.8%), and Omicron (55.9%).

The booster vaccine was more effective against Delta and Omicron, with an efficacy of 95.5% and 80.8%. The mRNA vaccine has higher vaccine efficacy against VOC.

Guidelines and Treatment Protocol

Following the recent rise in COVID-19 cases, the WHO has updated a few guidelines. Updated guidelines by the WHO recommend against using any new antiviral medication (VV116) for patients except in clinical trials.

WHO advises using analgesics in patients with a low risk of hospitalization. They do not advise using any anti-viral medication.

They advise against using ivermectin for patients with non-severe COVID-19. Ivermectin should only be used in clinical trials in critical COVID-19 patients.

WHO suggests using molnupiravir or remdesivir for high-risk patients if nirmatrelvir and ritonavir are unavailable.

WHO advises against using molnupiravir and remdesivir for moderate-risk patients as the cons outweigh the pros.

Conclusion

The WHO guidelines will keep on updating as the new variants continue to multiply. Henceforth, one must be conscious of the variants and the various nuances to deal with them.

Though the variants pose a threat to the healthcare system, the vaccine efficacy is like a glim of hope in the dark. The vaccine efficacy has substantially increased over the past few years enhancing the immunity against the virus.

Still, thorough research is necessary in this area to increase the vaccine effectiveness and reduce the virulence of the variants. Our healthcare system has been resilient enough to deal with the virus and continuous research will help us to keep the variants at par.

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors